Uncategorized Archives - Page 44 of 142

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical…

FridayAug 26, 2022 11:46 am

Study Explains How Threatening Cues Are Refined into Fear Signals

The fight-or-flight response is synonymous with most life forms. In moments of acute stress, your sympathetic nervous system will activate a sudden release of hormones that trigger a single response: fight or flight. Fear plays a major role in activating this response because it is usually activated in dire moments when a quick decision could be the difference between life and death. Scientists from the Salk Institute who were researching how the brain gathers threatening cues and distills them into fear signals have found a molecular pathway that plays a major role in creating the fear response. This pathway distills…

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

ThursdayAug 25, 2022 10:30 am

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by…

MondayAug 22, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial The MAD arm thus far shows that the drug is safe and well tolerated Odyssey expects to report additional MAD results as they become available A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC:…

WednesdayAug 17, 2022 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made…

TuesdayAug 16, 2022 10:30 am

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families. “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO. Patent covers formulation and preparation of CycloSam in the U.S. QSAM Biosciences (OTCQB: QSAM) has been awarded a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R). Granted by the U.S. Patent & Trademark Office, the patent “protects how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to…

ThursdayAug 11, 2022 9:30 am

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers Odyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts and allow interested investors to access information regarding the company The website redesign follows on the company’s name change earlier this year to similarly improve the expression of its brand identity Medical technology…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

Study Explains How Threatening Cues Are Refined into Fear Signals

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search